【热门产品推介】Research Grade Abituzumab，AntibodySystem Laboratories
Abituzumab（阿比妥珠单抗）是一种人源化抗整合素αV单克隆抗体(IgG2型)。Abituzumab可有效降低FAK、Akt和ERK的磷酸化。阿比妥珠单抗可用于癌症研究,尤其是前列腺癌
货号：DHC21901
产品链接：http://www.antibodysystem.com/product/188.html
寄主物种：Human
形式：Liquid
存储缓冲区：0.01M PBS, pH 7.4.
浓度：1 mg/ml
纯度：>95% by SDS-PAGE.
克隆性：Monoclonal
应用：Research Grade Biosimilar
介绍：Abituzumab是一种人源化抗 integrin αV 单克隆抗体 (IgG2 型)。Abituzumab 能有效减少 FAK、 Akt 和 ERK 的磷酸化。Abituzumab 可用于癌症，尤其是前列腺癌的研究。
储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
联系方式：027-65279366
参考文献：
Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression. PMID: 28314844
STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease. PMID: 33004536
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. PMID: 25319061
Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer. PMID: 26839144
Integrins as A New Target for Cancer Treatment. PMID: 30451118
Integration of NMR Spectroscopy in an Analytical Workflow to Evaluate the Effects of Oxidative Stress on Abituzumab: Beyond the Fingerprint of mAbs. PMID: 37278511
Integrin Inhibitors in Prostate Cancer. PMID: 29415418
Integrins as Therapeutic Targets: Successes and Cancers. PMID: 28832494
A novel therapeutic option for castration-resistant prostate cancer: after or before chemotherapy? PMID: 23838638
Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. PMID: 29893938
Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. PMID: 20031203
Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses. PMID: 24242902
A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy. PMID: 23791392
Abituzumab(DI17E6)(0.01、0.1、1、10、30100µg/mL；24小时)抑制PCa细胞与多种细胞外基质蛋白的粘附,但不抑制I型胶原[1]。Abituzumab(100µg/mL；12、18小时)抑制了PCa细胞的运动和侵袭[1]。Abituzumab(0.01、0.1、1、10、30100µg/mL；24小时)抑制PCa细胞粘附成骨细胞和骨基质细胞系的能力[1]。Abituzumab(100µg/mL；24小时)阻断PCa癌细胞系中整合素介导的细胞信号[1]。细胞活力测定[1]细胞系：PCa细胞浓度：0.01、0.1、1、10、30100µg/mL培养时间：24小时结果：促进PCa细胞从玻璃体凝集素(高达约20%的细胞以100μg/mL的速度脱落)、骨桥蛋白(高达大约10%的细胞以100ug/mL的速度分离)和纤维连接蛋白(高约10%的细胞在100μg/mL的速度剥离)上脱落,但不从I型胶原上脱落。细胞侵袭试验[1]细胞株：PCa细胞浓度：100µg/mL培养时间：12,18小时结果：与载体相比,侵袭能力被抑制了约25至30%,运动能力被抑制约30至40%。细胞活力测定[1]细胞系：PCa、hFOB、Saos2、HS-5、HDMEC细胞浓度：0.01、0.1、1、10、30100µg/mL培养时间：24小时结果：抑制PCa细胞与人成骨细胞系hFOB和Saos2以及骨髓基质细胞系HS-5的粘附。促进PCa细胞从αv整合素的已知表达者HDMEC中分离。Western Blot分析[1]细胞株：PC3、DU145、C4-2B、LNCaP、ARCaP和VCaP细胞浓度：100µg/mL培养时间：24小时结果：抑制了C4-2B和LNCaP分别在12小时和6小时开始的FAK磷酸化；C4-2B和LNCaP分别在3小时和2小时开始AKT磷酸化；和ERK磷酸化分别在C4-2B和LNCaP的1小时和1.5小时开始。
[1]. Jiang Y, et al. Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression. Mol Cancer Res. 2017 Jul;15(7):875-883
